First-line therapy and response in EBV+ DLBCL-NOS
| . | EBV+ DLBCL-NOS . | ≤50 y . | >50 y . | P . |
|---|---|---|---|---|
| First-line therapy, n | 69* | 23 | 46* | |
| Intent-to-cure therapy | 56 (81) | 23 (100) | 33 (72) | .003 |
| Immunochemotherapy ± RT | 41 (73) | 16 (70) | 25 (76) | .760 |
| Chemotherapy ± RT, n (%) | 15 (27) | 7 (30) | 8 (24) | |
| ASCT | 3 (4) | 3 (13) | 0 | .03 |
| Palliative care | 13 (19) | 0 | 13 (28) | |
| Response to first-line intent-to-cure therapy, n | 56 | 23 | 33 | |
| CR | 41 (73) | 21 (91) | 20 (61) | .014 |
| PD | 10 (18) | 0 | 10 (30) | .003 |
| NA (death other cause) | 5 (9) | 2 (9) | 3 (9) | >.99 |
| Follow-up and survival, n | 70 | 23 | 47 | |
| Median follow-up, months | 48 | 43.5 | 48 | |
| Median PFS, months | NR | NR | 6.6 | |
| Median OS, months | NR | NR | 10.9 |
| . | EBV+ DLBCL-NOS . | ≤50 y . | >50 y . | P . |
|---|---|---|---|---|
| First-line therapy, n | 69* | 23 | 46* | |
| Intent-to-cure therapy | 56 (81) | 23 (100) | 33 (72) | .003 |
| Immunochemotherapy ± RT | 41 (73) | 16 (70) | 25 (76) | .760 |
| Chemotherapy ± RT, n (%) | 15 (27) | 7 (30) | 8 (24) | |
| ASCT | 3 (4) | 3 (13) | 0 | .03 |
| Palliative care | 13 (19) | 0 | 13 (28) | |
| Response to first-line intent-to-cure therapy, n | 56 | 23 | 33 | |
| CR | 41 (73) | 21 (91) | 20 (61) | .014 |
| PD | 10 (18) | 0 | 10 (30) | .003 |
| NA (death other cause) | 5 (9) | 2 (9) | 3 (9) | >.99 |
| Follow-up and survival, n | 70 | 23 | 47 | |
| Median follow-up, months | 48 | 43.5 | 48 | |
| Median PFS, months | NR | NR | 6.6 | |
| Median OS, months | NR | NR | 10.9 |
Data are presented as n (%) of patients, unless otherwise indicated.
ASCT, autologous stem cell transplantation; HL, Hodgkin lymphoma; NA, not assessed; NR, not reached; PR, partial response; RT, radiation therapy.
Missing data (n = 1).